Shah Rahimian

Biography

Dr. Shah Rahimian is the Vice President of Clinical Development and Regulatory Affairs at Targazyme, Inc. With over 17 years of experience in medicine and clinical research, he leads the company on its path of development both nationally and internationally. He is a successful entrepreneur information and growth of bioscience companies and a recognized leader in the biotechnology and pharmaceutical development industry. Before joining Targazyme, he derived critical development and regulatory strategies in parallel with commercialization of cell based and biologic products at Antria, Inc where the company became received the very first IND approval to initiate clinical trials with adipose derived stem cells in the US. Prior to his assignment at Antria, Dr. Rahimian was the Vice President of Clinical Research at Illumina. His achievements include successful conduct of over 60 clinical trials globally and building strategic partnerships with healthcare facilities and world’s top 10 biotechnology and pharmaceutical companies. He provides consulting services to major biotechnology and pharmaceutical companies in Oncological drug development, Regenerative medicine for plastic and reconstructive surgery and orthopedics, drug safety, regulatory affairs, commercialization and strategic planning since 2003. Dr. Rahimian has an MD, degree from the University of Istanbul and a CRA degree from the University of South Carolina. He has completed fellowships in general and oncological surgery, multiple teaching assignments with numerous publications and academic awards.

Research Interest

Clinical Development